$NXTS News

Nexentis Technologies Subsidiary MitoCareX Bio Narrows Its SLC Transport Protein Candidates To Select Candidate For A Drug Discovery Campaign

Nexentis Technologies Files Prospectus For Offering 2.573M Common Shares On Behalf Of Selling Shareholders

Nexentis Technologies Subsidiary Completes Analysis Of SLC Transport Proteins, Starts Global AI Drug Discovery Initiative With Boltz

Nexentis Shares Rise After Solar Project Monetisation Agreement (NXTS)

Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment

Nexentis Technologies Amends Its Loan And Partnership Agreement With Solterra Renewable Energy, Other Lenders For Melz Solar Project; Solterra To Make Early Partial Repayments Of ~$147K On Its Part Of Loan, $98K For Sale Of 10% Of Its Profit Rights;

Nexentis Technologies Files Prospectus For Offering 410,998 Common Shares At $7.056/Share

Nexentis Technologies Soars 156% Before Falling 46% After Hours — Here’s Why NXTS Stock Is Trending

Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery

Nexentis Technologies Subsidiary MitoCareX Bio Partners With AI Biomolecular Drug Discovery Research Lab Boltz To Accelerate Identification Of Novel Small-Molecule Scaffolds Targeting Selected Solute Carrier Proteins

Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases

Nexentis Technologies Subsidiary Completes Structural Analysis Of Human Solute Carrier Transport Protein

Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development

Nexentis Subsidiary MitoCareX Hits First Drug‑Discovery Milestone With Optimized Molecule

Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone

Nexentis Technologies Announces U.S. Trademark Registration Approval for MitoCareX’s Algorithm Platform MITOLINE™

Nexentis Technologies' Subsidiary Receives U.S. Patent And Trademark Office Official Trademark Registration For Its MITOLINE Algorithm Platform

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Nexentis Technologies Inc. Launches New Corporate Website, Showcasing Innovative AI-Driven Biotech Platform